2012
DOI: 10.1111/j.1939-1676.2012.01026.x
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: BackgroundThe benefit of pimobendan in delaying the progression of preclinical dilated cardiomyopathy (DCM) in Dobermans is not reported.HypothesisThat chronic oral administration of pimobendan to Dobermans with preclinical DCM will delay the onset of CHF or sudden death and improve survival.AnimalsSeventy-six client-owned Dobermans recruited at 10 centers in the UK and North America.MethodsThe trial was a randomized, blinded, placebo-controlled, parallel group multicenter study. Dogs were allocated in a 1:1 r… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

6
91
0
3

Year Published

2013
2013
2020
2020

Publication Types

Select...
5
5

Relationship

0
10

Authors

Journals

citations
Cited by 131 publications
(100 citation statements)
references
References 28 publications
6
91
0
3
Order By: Relevance
“…Thus, benazepril or methyldigoxin monotherapy were comparatively less effective than pimobendan. These findings complement those observed in the PROTECT study21 that identified improved survival in Doberman pinscher dogs with preclinical DCM that received pimobendan compared with placebo. Others have reported short‐term hemodynamic and neuroendocrine benefits in pimobendan‐treated dogs with CHF associated with MMVD compared with benazepril‐treated dogs, including larger decreases in heart rate, left atrial size, systolic and diastolic left ventricular diameters and volumes, and increased ejection fraction 27.…”
Section: Discussionsupporting
confidence: 83%
“…Thus, benazepril or methyldigoxin monotherapy were comparatively less effective than pimobendan. These findings complement those observed in the PROTECT study21 that identified improved survival in Doberman pinscher dogs with preclinical DCM that received pimobendan compared with placebo. Others have reported short‐term hemodynamic and neuroendocrine benefits in pimobendan‐treated dogs with CHF associated with MMVD compared with benazepril‐treated dogs, including larger decreases in heart rate, left atrial size, systolic and diastolic left ventricular diameters and volumes, and increased ejection fraction 27.…”
Section: Discussionsupporting
confidence: 83%
“…Therefore, only patients in advanced disease stages were selected and it would have been unethical not to treat those dogs. All dogs received the same background therapy (Pimobendan and ACE-inhibitors), but antiarrhythmic therapy was individualized [15,101]. Antiarrhythmic therapy was adjusted according to the patient’s individual electrocardiographic changes and was therefore not completely homogenous.…”
Section: Discussionmentioning
confidence: 99%
“…Advice given to the owner would be that this dog is likely to be at risk of sudden death and that there is likely to be progression of the systolic dysfunction, resulting in signs of congestive heart failure at some point in the future. However, it has been shown by Summerfield and others (2012) that administration of pimobendan during the preclinical stage of this disease can potentially postpone these outcomes by around nine months.…”
Section: Common Tachydysrhythmiasmentioning
confidence: 99%